Abound Wealth Management’s Bionano Genomics BNGO Stock Holding History

Abound Wealth Management’s Portfolio BNGO Stock Details BNGO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-3	Closed	-$69	–	1244
2024 Q3	$69	Buy	+3	New	+$93	﹤0.01%	1288

Other funds holding BNGO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Abound Wealth Management's BNGO Position: Q4 2024 in Review

Abound Wealth Management sold out of Bionano Genomics (BNGO) in Q4 2024, closing a stake of 3 shares — an estimated $69 sold.

Abound Wealth Management first reported a position in BNGO in Q3 2024 and held it in 1 quarter. The position peaked at $69 in Q3 2024. 50 funds tracked by Wall St. Rank hold BNGO as of Q4 2024.

Abound Wealth Management reported no remaining Bionano Genomics position as of Q4 2024 after selling out during the quarter.
Abound Wealth Management sold 3 Bionano Genomics shares in Q4 2024, an estimated $69.
Abound Wealth Management first reported a position in Bionano Genomics in Q3 2024 and held it in 1 quarter.
Abound Wealth Management's Bionano Genomics position peaked at $69 in Q3 2024.
50 funds tracked by Wall St. Rank held Bionano Genomics as of Q4 2024.

Based on Abound Wealth Management's 13F filing for Q4 2024, filed 13 Jan 2025.